BioTime (BTX) : Broadwood Capital Inc scooped up 2,732,636 additional shares in BioTime during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 24,897,032 shares of BioTime which is valued at $77,678,740.BioTime makes up approximately 13.22% of Broadwood Capital Inc’s portfolio.
Other Hedge Funds, Including , Aqr Capital Management reduced its stake in BTX by selling 24,540 shares or 70.54% in the most recent quarter. The Hedge Fund company now holds 10,248 shares of BTX which is valued at $31,974.Rhumbline Advisers boosted its stake in BTX in the latest quarter, The investment management firm added 5,270 additional shares and now holds a total of 48,181 shares of BioTime which is valued at $150,325.Vanguard Group Inc boosted its stake in BTX in the latest quarter, The investment management firm added 408,901 additional shares and now holds a total of 2,424,713 shares of BioTime which is valued at $7,565,105.Blackrock Fund Advisors boosted its stake in BTX in the latest quarter, The investment management firm added 208,613 additional shares and now holds a total of 1,675,378 shares of BioTime which is valued at $5,227,179.
BioTime closed down -0.1 points or -3.40% at $2.84 with 1,94,287 shares getting traded on Thursday. Post opening the session at $2.88, the shares hit an intraday low of $2.8 and an intraday high of $2.9 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
BioTime Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines including tissue banking cellular therapy gene therapy and tissue engineering. The Company is engaged to develop cell-based therapeutic products for diseases such as neurological disorders cancer age related macular degeneration orthopedic disorders and age-related cardiovascular disease.